Santa Fe New Mexican

Possible Purdue resolution in sight

Bankruptcy court filings indicate support for the plan to reorganize the maker of OxyContin

- By Geoff Mulvihill

NEW YORK — Purdue Pharma’s quest to settle thousands of lawsuits over the toll of OxyContin and its other prescripti­on opioid painkiller­s entered its final phase Thursday with the grudging support of many of those who have claims against the company.

But the lingering opposition from some state attorneys general took center stage in the first day of a confirmati­on hearing in U.S. Bankruptcy Court about the company’s reorganiza­tion plan.

Questions from a lawyer representi­ng Connecticu­t voiced the concern that states are being forced to accept the deal with both Purdue and members of the wealthy Sackler family who own the company.

The attorney, Irve Goldman, essentiall­y asked John Dubel, a corporate turnaround expert who was installed as a member of Purdue’s board of directors two years ago, why states should not go to trial.

“Is it a reasonable view for a creditor or sovereign state to want their claims resolved through an adversaria­l process so their view of justice should be served?” Goldman asked.

Dubel said he understood that states have that complaint, but added: “We have 95-plus percent support from all of our creditors” and that the Sacklers’ planned contributi­on to the settlement is “fair and equitable.”

The confirmati­on hearing, which could stretch out over two weeks, comes nearly two years after Purdue filed for bankruptcy as a way to settle about 3,000 legal claims filed against it by state and local government­s, Native American tribes and others.

In addition to cash from the Sacklers, the company is asking a judge to approve the company being remade into an entity that’s no longer owned by the family, with its profits dedicated to abating the opioid crisis.

As Dubel noted, most of the groups with claims against Purdue are on board with the settlement plan after years of negotiatio­ns.

Those with claims against Purdue were given a vote on the settlement, though U.S. Bankruptcy Judge Robert Drain is not bound by the results. Well over 90 percent of most groups of creditors said they approved, according to court filings.

On Thursday, an official with the company that counted the votes acknowledg­ed that the support reflects only those who cast ballots. The majority of the more than 600,000 people and entities who were eligible to vote did not.

A group of Democratic state attorneys general were among the last to get on board. Until July, top state government lawyers were divided nearly evenly on whether to accept the deal.

Several of the opponents signed on after Purdue agreed to make many company records public and Sackler family members agreed to accelerate payments and increase payments. They’ve now agreed to provide a total of $4.5 billion in the form of cash and control of a charitable fund.

In response to questions, Dubel also said that the possibilit­y that the settlement would fall apart is why the company has not shared with the court communicat­ions from its lawyers about the legal risks faced by the Sacklers.

“We are still not certain that this plan will be confirmed,” he testified, “and we don’t have full certainty that the payments will be made over the next nine years.”

An analysis commission­ed by a group of state attorneys general before changes in the agreement found the estimated wealth of the Sackler family could rise from $10.7 billion in 2020 to $14.6 billion by 2030 because of investment returns and interest.

David Sackler, a grandson of one of the three brothers who nearly 70 years ago bought the company that became Purdue, made a written declaratio­n in court supporting the settlement and could be called to testify on it in the coming days.

 ?? SETH WENIG/ASSOCIATED PRESS ?? Jayde Newton helps to set up cardboard gravestone­s with the names of victims of opioid abuse Monday outside the courthouse where the Purdue Pharma bankruptcy hearing is taking place in White Plains, N.Y. Purdue Pharma’s quest to settle thousands of lawsuits over the toll of OxyContin and restructur­e the company is entering its final phase.
SETH WENIG/ASSOCIATED PRESS Jayde Newton helps to set up cardboard gravestone­s with the names of victims of opioid abuse Monday outside the courthouse where the Purdue Pharma bankruptcy hearing is taking place in White Plains, N.Y. Purdue Pharma’s quest to settle thousands of lawsuits over the toll of OxyContin and restructur­e the company is entering its final phase.

Newspapers in English

Newspapers from United States